论文部分内容阅读
Fedotozine(F)是一种新型表面鸦片类受体的配体,法国、比利时和突尼斯的68个中心用双盲多中心方法比较F三种剂量(3.5、15和30mg,tid)与安慰剂治疗肠易激综合征的效应和安全性。 在剔除316例中对2周安慰剂(P)试验有反应者后,余238例患者(男88例,女150例,平均47.2±12.2岁)随机分成四组作6周治疗,其中198例患者完成试验。 受试者年龄为18～65岁,每周至少有3次中等强度以上的下腹部疼痛(或不适),伴有两种以上典型的
Fedotozine (F), a novel ligand for surface opioid receptors, was compared in a double-blind, multicentre, 68-center French, Belgian, and Tunisian-based trial comparing F three doses (3.5, 15 and 30 mg tid) with placebo Irritable bowel syndrome effect and safety. Of the 316 patients who responded to the two-week placebo (P) trial, 238 patients (88 males, 150 females, mean 47.2 ± 12.2 years) were randomly assigned to four groups for six weeks of treatment, of whom 198 The patient completed the test. Subjects were 18 to 65 years of age with at least 3 moderate lower abdominal pain (or discomfort) per week, with two or more typical